Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

s0099997

—

e1a45b94-0ccb-50d0-b05d-8fe30dff0b6e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.600
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
  • TNFA_SIGNALING_VIA_NFKB+0.500
  • CHOLESTEROL_HOMEOSTASIS+0.400
  • COAGULATION+0.400
  • INFLAMMATORY_RESPONSE+0.400
  • OXIDATIVE_PHOSPHORYLATION+0.400
  • APICAL_JUNCTION+0.300
  • COMPLEMENT+0.300
  • ESTROGEN_RESPONSE_EARLY+0.300

Top 10 suppressed

  • E2F_TARGETS-0.400
  • G2M_CHECKPOINT-0.400
  • MYC_TARGETS_V2-0.400
  • INTERFERON_ALPHA_RESPONSE-0.200
  • MITOTIC_SPINDLE-0.200
  • MYC_TARGETS_V1-0.200
  • PI3K_AKT_MTOR_SIGNALING-0.200
  • WNT_BETA_CATENIN_SIGNALING-0.200
  • ALLOGRAFT_REJECTION-0.100
  • DNA_REPAIR-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-AN-A03X-01A-21R-A00Z-07
breast-umap@18
—A0.889
2SRR8518353
breast-umap@18
—F0.883
3TCGA-CN-4726-01A-01R-1436-07
head-neck@1
——0.869
4SRR15030843
colon-landscapes@1
——0.864
5TCGA-BH-A0HF-01A-11R-A056-07
breast-umap@18
—A0.864
6TCGA-BH-A0DX-01A-11R-A115-07
breast-umap@18
—A0.860
7MNG329
mng-umap@100
——0.853
8TCGA-BA-5557-01A-01R-1514-07
head-neck@1
——0.836
9MDT-AP-0385
medullo-epn-umap@date-based
MedMedulloblastoma0.834
10C3N-04173
lung-landscapes@6
—cohortA20.832

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 35 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.600Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.500Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.500Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.400Remibrutinib— uncovered
COAGULATION0.400Binimetinib— uncovered
INFLAMMATORY_RESPONSE0.400Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.400Remibrutinib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
COMPLEMENT0.300Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.300Inavolisib— uncovered
FATTY_ACID_METABOLISM0.300Inavolisib— uncovered
HYPOXIA0.300Idelalisib— uncovered
KRAS_SIGNALING_UP0.300Inavolisib— uncovered
TGF_BETA_SIGNALING0.300Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.300Inavolisib— uncovered
ADIPOGENESIS0.200Inavolisib— uncovered
ANDROGEN_RESPONSE0.200Inavolisib— uncovered
APICAL_SURFACE0.200Temsirolimus— uncovered
APOPTOSIS0.200Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.200Idelalisib— uncovered